Therapeutic Photobiomodulation and Tretament of Spasticity
28 patients around the world
Available in Brazil
Cerebral palsy is a non-progressive, permanent syndrome that occurs in childhood and is
accompanied by motor, tonus and posture disorders. Its etiology is related to an insult
or damage to the central nervous system in maturation, during the prenatal, perinatal or
postnatal period, when the central nervous system has not yet fully developed.
Approximately 80% of cerebral palsy course with spasticity, which, when left untreated,
will generate pain and functional, anatomical and structural changes in bones, joints,
muscles, tendons and nerve junctions, with a negative impact on quality of life, social
participation and functionality of this individual. In parallel, photobiomodulation
therapy has biological effects of tissue regeneration, muscle relaxation, vasodilation,
reduction of the inflammatory process and relief of pain symptoms already described in
the literature, in addition to being feasible, practical, safe, without side effects,
painless and non-invasive.Objectives and methods: this study is a pilot, double-blind,
randomized and controlled clinical trial that will evaluate the effect of
photobiomodulation in reducing gastrocnemius muscle spasticity in 28 children aged 2 to
18 years, diagnosed with spastic cerebral palsy of right lower limb of any etiology for
at least 03 months, selected at the
Physiotherapy Service of Universidade Nove de Julho and randomized into two groups:
application of Low Intensity LED Therapy in the medial and right lateral gastrocnemius
muscles (device power of 100mW, wavelength of 850nm, energy of 1.5 J/point, applied in 02
points per muscle, for 15 seconds, frequency of once a week, making 8 therapeutic days)
or placebo group Low-Intensity LED Therapy (same device turned off). Patients with fixed
anatomical deformity of the ankle with less than 90 degrees of dorsiflexion amplitude,
malnutrition, severe gastroesophageal reflux disease and another type of associated
movement disorder will be excluded. Both groups will also receive the standard treatment
for spasticity performed by the hospital's rehabilitation health team.
To assess the response to therapy, the outcomes evaluated will be the modified Ashworth
Scale (MAS), the Mobility Domain of Pediatric Evaluation of Disability Inventory for
children (PEDI), the Gross Motor Function Classification System scale (GMFCS) and passive
range of motion (ROM) of the ankle analyzed at the end of each therapeutic session and in
the pre therapeutic period of 08 weeeks. Epidemiological data will be collected from the
medical records of participants in the physiotherapy for characterizing the sample (age,
gender,etiology of brain injury and type of paralysis, injury time, medications,
comorbidities, previous surgeries, length of physiotherapy treatment at the start of the
study, description of the physiotherapy treatment in use, use of a walking aid or
orthosis. Data will be statistically analyzed and positive or negative results reported
and discussed.